Lavipharm

Lavipharm Debt

The Debt of Lavipharm (LAVI.AT) as of Nov 16, 2026 is 28.37 M EUR. In the previous year, Debt was 33.82 M EUR — a change of -16.12% (lower).

Debt

28.37 MEUR

YoY

-16.12%

Last updated:

In 2025, Lavipharm's total debt was 28.37 M EUR, a -16.12% change from the 33.82 M EUR total debt recorded in the previous year.

The Lavipharm Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
40.54 M EUR
Jan 1, 2019
40.71 M EUR
Jan 1, 2020
36.26 M EUR
Jan 1, 2021
37.33 M EUR
Jan 1, 2022
37.07 M EUR
Jan 1, 2023
32.37 M EUR
Jan 1, 2024
33.82 M EUR
Jan 1, 2025
28.37 M EUR
The Lavipharm Debt history
YEARDebtYoY
28.37 MEUR-16.12%
33.82 MEUR+4.46%
32.37 MEUR-12.67%
37.07 MEUR-0.70%
37.33 MEUR+2.95%
36.26 MEUR-10.94%
40.71 MEUR+0.41%
40.54 MEUR-2.26%
41.48 MEUR-47.53%
79.07 MEUR-3.41%
81.86 MEUR+32.04%
61.99 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lavipharm Stock analysis

What does Lavipharm do? Lavipharm SA manufactures and imports pharmaceuticals and veterinary products, with main categories including anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological, and gastrointestinal therapies. The company offers cosmetic products under the brands Castalia Soins Dermocosmetiques and Laviderm Active Technology for skin, face, body, scalp, and hair care. Its OTC products encompass cold and flu remedies, oral care, dermatological items, condoms, antiseptics, analgesics, laxatives, and gynecology products. The company is the parent of Lavipharm Group of Companies and previously sold HITEX, a carbon dioxide extraction subcontracting business, to Robertet SA and CODIF in January 2014. Lavipharm SA's revenue streams come from the sale of pharmaceuticals, veterinary products, cosmetics under Castalia and Laviderm, and OTC products. Pharmaceutical and veterinary products target healthcare providers and pharmacies, while cosmetics and OTC products are sold directly to consumers through retail channels. The company's brand portfolio includes Castalia Soins Dermocosmetiques, Laviderm Active Technology, and its core pharmaceutical lines, with segments defined by product categories and distribution channels. The company's primary customers are healthcare professionals and retail consumers, with pharmaceuticals distributed via pharmacies and veterinary products to animal care facilities. Cosmetic products under Castalia and Laviderm are sold to consumers for personal care, and OTC products reach consumers through general retail. The sale of HITEX to Robertet SA and CODIF in 2014 was a one-time transaction that contributed to the company's financials during that period. Lavipharm is one of the most popular companies on Eulerpool.

Debt Details

Understanding Lavipharm's Debt Structure

Lavipharm's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Lavipharm's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Lavipharm’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Lavipharm’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Lavipharm stock

Debt of Lavipharm is 28.37 M EUR in 2025.

Debt of Lavipharm changed from 33.82 M EUR to 28.37 M EUR, representing a -16.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Lavipharm since 2006 – with annual values, charts, and detailed analysis.

Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Lavipharm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Lavipharm

All Key Metrics — Lavipharm